NEWS

WIRES

OTHER

CorMedix Enlists World-Class Panel to Advise On Cardiorenal Medicine

SUMMIT, N.J., Jan. 8, 2008 (PRIME NEWSWIRE) -- CorMedix Inc., a biopharmaceutical company, today announced that it had established an advisory panel of world-renowned physicians with special expertise in cardiorenal disease -- the epidemic intersection of cardiovascular disease and renal (chronic kidney) disease.

"As our name suggests, CorMedix is a hub of professional activity that emphasizes 'treating the kidney to treat the heart' -- and our new Cardiorenal Advisory Board will be at the epicenter," said Bruce C. Cooper, M.D., President and Chief Executive Officer. "These outstanding physicians will provide the high-level critical thinking and cutting-edge expertise we will require as we work to become the preeminent innovator in an exciting, challenging area of medicine."

The CorMedix Cardiorenal Advisory Board represents the fields of nephrology, diabetes and endocrinology, and cardiology:

 * Vivian Fonseca, M.D., Professor of Medicine, Director of the
   Diabetes Program, and Tullis-Tulane Alumni Chair in Diabetes,
   Tulane University Medical Center;

 * Charles Herzog, M.D., Director of the Echocardiography Laboratory
   at Hennepin County Medical Center; Professor of Medicine at the
   University of Minnesota; and Director of the Cardiovascular Special
   Studies Center, United States Renal Data System;

 * Adeera Levin, M.D., Professor of Medicine at the University of
   British Columbia, Canada, and Chair of the U.S. National Kidney
   Foundation's Kidney Disease Outcomes Quality Initiative; and

 * Giuseppe Remuzzi, M.D., Director of the Negri Bergamo Laboratories
   of the Mario Negri Institute for Pharmacological Research in
   Bergamo, Italy; and Director of the Department of Immunology and
   Clinical Transplantation of the Ospedali Riuniti di Bergamo.

"We look forward to benefiting from the Cardiorenal Advisory Board's invaluable insights and counsel," said Mark T. Houser, M.D., M.B.A., CorMedix's Chief Medical Officer. "These are some of the finest scientific minds and most prominent medical opinion leaders to be found anywhere in the world."

Dr. Houser said that the new Cardiorenal Advisory Board will provide:

 * Feedback and advice regarding unmet medical needs and new
   therapeutic options that can significantly improve the outcomes and
   quality of life for patients with cardiorenal diseases;
 * Guidance on the design and conduct of clinical studies;
 * Medical/scientific data on cardiorenal diseases and treatment
   breakthroughs; and
 * Product development strategies and in-licensing opportunities.

Background on the CorMedix Cardiorenal Advisory Board

Vivian Fonseca, M.D.

At Tulane University Medical Center, Dr. Fonseca is a Professor of Medicine, Director of the Diabetes Program, and Tullis-Tulane Alumni Chair in Diabetes. He is a recognized expert in the prevention and treatment of diabetic complications and cardiovascular disease. He has authored or co-authored more than 200 professional publications and is Editor-in-Chief of Diabetes Care and of Journal of the Metabolic Syndrome.

Charles Herzog, M.D.

Dr. Herzog is Director of the Cardiovascular Special Studies Center, United States Renal Data System. He has been a cardiologist at Hennepin County Medical Center (HCMC) in Minneapolis. A University of Minnesota faculty member for 23 years, he has been Professor of Medicine since 2004. Since 1985 he has been the cardiology consultant to the ESRD program at HCMC (dialysis and renal transplantation). He founded the program in interventional cardiology and served as Director of the Cardiac Catheterization Laboratory at HCMC from 1985 to 1991. Since 1997 he has been Director of the HCMC Cardiac Ultrasound Laboratory. Dr. Herzog is a Fellow of the American College of Cardiology. His areas of research or special interest include cardiac disease and ESRD and echocardiography. He is a member of the editorial boards of American Heart Journal, Journal of Nephrology, and Clinical Journal of the American Society of Nephrology. He is a liaison editor (cardiology) for Nephrology Dialysis Transplantation.

Adeera Levin, M.D.

Dr. Levin is an internationally recognized figure in nephrology. She is Professor of Medicine at the University of British Columbia, Canada, and has been Chair of the U.S. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative since 2003. Since 1990, she has developed a series of multi-center observational and interventional trials with Canadian and international investigators, focusing on cardiovascular disease in early chronic kidney disease populations. She has published more than 135 peer-reviewed articles, and serves on editorial boards for a number of nephrology journals, including Nephrology Dialysis Transplantation, American Journal of Kidney Diseases, and Journal of the American Society of Nephrology.

Giuseppe Remuzzi, M.D.

Professor Remuzzi is Director of the Negri Bergamo Laboratories of the Mario Negri Institute for Pharmacological Research and Director of the Department of Immunology and Clinical Transplantation of the Ospedali Riuniti di Bergamo, Italy. In these positions he leads a diverse team of clinicians and researchers studying human renal diseases and experimental models for pathophysiological study and therapeutic intervention. Professor Remuzzi is recognized as an international expert in renal disease. An author or co-author of more than 920 scientific articles, he serves on the editorial boards of many journals, including the New England Journal of Medicine.

About CorMedix Inc.

A biopharmaceutical company based in Summit, New Jersey (20 miles from New York City), CorMedix focuses on treating cardiorenal diseases. Its signature approach is "Treating the Kidney to Treat the Heart." CorMedix has a Phase III development program supported by a Special Protocol Assessment with the U.S. Food and Drug Administration for a single pivotal trial of deferiprone, a unique iron chelator that concentrates in an active form in the kidney. CorMedix's DEFEND-AKI Study will be the largest multi-center, multi-national study of actual clinical outcomes in patients who are at the highest risk for contrast-induced nephropathy. The acronym "DEFEND-AKI" stands for: "DEFeriprone for the Reduction of ENDpoints Associated with Acute Kidney Injury Following the Administration of Iodinated Contrast."

CONTACT:  CorMedix Inc.
          Mark T. Houser, M.D., M.B.A, Chief Medical Officer
            908-517-9487
          Bruce C. Cooper, M.D., President and Chief Executive Officer
            908-517-9486
          www.cormedix.com